Remove Immune Response Remove Presentation Remove RNA
article thumbnail

Decoding stem cells for personalised regenerative medicine

Drug Target Review

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. In the lab, they labelled RNA molecules with fluorescent markers, enabling them to easily locate them within individual cells.

RNA 128
article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA Therapeutics: Revolutionizing Treatment Beyond Vaccines

DrugBank

Introduction Messenger RNA (mRNA) technology has emerged as one of the most significant medical breakthroughs. Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. Another challenge is the potential for unintended immune responses.

Vaccine 97
article thumbnail

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

Drug Target Review

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

article thumbnail

AstraZeneca COVID-19 Vaccine Shows Good Results in Late Trials

The Pharma Data

“The results presented in this report provide the key findings from our first interim analysis,” study author Merryn Voysey, also from the University of Oxford, said in a journal news release. Both employ a newer technology that uses messenger RNA to prime the immune system to attack the new coronavirus.

Vaccine 52
article thumbnail

CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV

The Pharma Data

To identify strains causing COVID-19 infections within the trial, sequencing of virus variants has so far been performed on 474 COVID-19 cases, of which 124 fulfilled adjudication criteria and were included in the present efficacy analysis. CureVac remains committed to COVID-19 vaccine development. About CureVac.

Vaccine 52
article thumbnail

Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021

The Pharma Data

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Oral presentation. Interim Phase 1/2 study data will be presented at ISTH. Oral Presentation. ePoster Abstract # OC48.2 Abstract # OC72.2